2024年11月23日，先为达生物发布消息——收到国家药品监督管理局下发的《受理通知书》，公司提交的1类新药伊诺格鲁肽注射液（Ecnoglutide Injection）成人2型糖尿病患者血糖控制的适应症上市许可申请获国家药品监督管理局受理。 关于伊诺格鲁肽注射液（Ecnoglutide ...

2024年11月23日，先为达生物发布消息——收到国家药品监督管理局下发的《受理通知书》，公司提交的1类新药伊诺格鲁肽注射液（Ecnoglutide Injection ...

This collaboration highlights the global commercialization potential of Sciwind's innovative pipeline and lays a solid foundation for the worldwide development and potential commercialization of key ...

Oral Ecnoglutide (Ecnoglutide Oral, XW004): A phase 2-ready, potential first-in-class, once-weekly oral GLP-1 receptor agonist Oral Amylin Receptor Agonist (Amylin RA): A potential first-in-class ...

About Oral Ecnoglutide (XW004): Glucagon-like peptide-1 (GLP-1) agonists are effective in treating type 2 diabetes and obesity and show potential in treating MASH as well as obesity-related ...

Oral Ecnoglutide (Ecnoglutide Oral, XW004): A phase 2-ready, potential first-in-class, once-weekly oral GLP-1 receptor agonist Oral Amylin Receptor Agonist (Amylin RA): A potential first-in-class, ...